Abstract
Rats were treated once with doses of haloperidol or of droperidol below and above the acute ID50 vs the dopamine agonist apomorphine; they were later challenged with an acute dose of apomorphine (0.3mg/kg, SC) and rated for stereotyped behavioral responses. The two neuroleptics were similar in acute anti-apomorphine potency (ID50=0.12 and 0.18mg/kg for haloperidol and droperidol, respectively). The antidopaminergic effects of droperidol persisted for nearly 1 week and those of haloperidol lasted for 20–40 days, depending on the dose given. The computed half-time of disappearance of their antidopaminergic effects was 7.6±1.0 days and 0.59±0.17 days for haloperidol and droperidol, respectively, following a dose of 0.3 mg/kg, and these indices of duration of action did not vary significantly at doses between 0.1 and 1.0mg/kg. Haloperidol reduced the acute entry of 3H-apomorphine into brain by 21.5% 1 week later. Treatment with apomorphine alone just prior to haloperidol (both at 0.3 mg/kg) prevented the prolonged antidopaminergic effects of the neuroleptic evaluated 1 week later. These results indicate that some neuroleptics may have very prolonged activity or retention in tissue at sites of action, even after moderate, single doses. Caution is recommended in the interpretation of studies which assume “neuroleptic-free” conditions of subjects previously exposed to a neuroleptic agent.
Similar content being viewed by others
References
Antelman SM, Kocan D, Edwards DJ, Fraser M, Perel J, Knopf S (1983) Haloperidol catalepsy shows sensitization which depends on passage of time rather than repeated treatment. Neurosci Soc Abs 9:566
Baldessarini RJ (1980) Drugs and the treatment of psychiatric disorders. Chapt 19. In: Gilman AG, Goodman LS, Gilman A (eds) The pharmacologic basis of therapeutics. MacMillan Co, New York, pp 391–447
Baldessarini RJ (1984) Antipsychotic agents. In: Karasu TB (ed) The psychiatric therapies, Part I: The somatic therapies. The American Psychiatric Association, Washington DC, pp 119–170
Baldessarini RJ, Katz B, Cotton P (1984) Dissimilar dosing with high-potency and low-potency neuroleptics. Am J Psychiatry 141:748–752
Breyer U, Gaertner HJ (1974) Tissue accumulation of metabolites during chronic administration of piperazine-substituted phenothiazine drugs. In: Forrest IS, Carr CJ, Usdin E (eds) The phenothiazines and structurally related drugs. Raven Press, New York, pp 167–173
Campbell A, Baldessarini RJ (1981) Tolerance to behavioral effects of prolonged administration of haloperidol. Life Sci 29:1341–1346
Campbell A, Baldessarini RJ (1982) Circadian changes in behavioral effects of haloperidol in rats. Psychopharmacology 77:150–155
Campbell A, Baldessarini RJ, Ram VJ, Neumeyer JL (1982) Behavioral effects of (-)10,11-methylenedioxy-N-n-propylnorapomorphine, an orally effective long-acting agent active at central dopamine receptors, and analogous apomorphines. Neuropharmacology 21:953–961
Campbell A, Baldessarini RJ, Teicher MH, Neumeyer JL (1985) Behavioral effects of apomorphine isomers in the rat: Selective locomotor-inhibitory effects of S(+)N-n-propylnorapomorphine. Psychopharmacology (in press)
Campbell A, Herschel M, Cohen BM, Baldessarini RJ (1980) Tissue levels of haloperidol by radioreceptor assay and behavioral effects of haloperiodol in the rat. Life Sci 27:633–640
Cohen BM, Herschel M, Miller E, Mayberg H, Baldessarini RJ (1980) Radioreceptor assay of haloperidol tissue levels in the rat. Neuropharmacology 19:663–668
Curry SH (1976) Metabolism and kinetics of chlorpromazine in relation to effect. In: Sedvall G, Uvnäs B, Zotterman Y (eds) Antipsychotic drugs: Pharmacodynamics and pharmacokinetics. Pergamon Press, New York, pp 343–352
DeLean A, Munson PJ, Rodbard D (1978) Simultaneous analysis of families of sigmoidal curves: Application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 4(2):E97-E102
Forrest IS, Forrest FM (1963) On the metabolism and action mechanism of the phenothiazine drugs. Exp Med Surg 21:231–240
Forrest IS, Fox J, Green DE, Melikia AP, Serra MT (1974) Total excretion of 3H-chlorpromazine and 3H-prochlorperazine in chronically dosed animals: Balance sheet. In: Forrest IS, Carr CJ, Usdin E (eds) The phenothiazines and structurally related drugs. Raven Press, New York, pp 347–356
Janssen PAJ, Van Bever WFM (1978) Structure-activity relationships of the butyrophenones and diphenylbutyloiperidines. Chapt 1 in Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology, Vol 10. Plenum Press, New York, pp 1–35
Kebabian JW (1978) A sensitive enzymatic-radioisotopic assay for apomorphine. J Neurochem 30:1143–1148
Keppel G (1973) Design and Analysis: A Researcher's Handbook. Prentice-Hall, Englewood Cliffs, New Jersey
Madsen JR, Campbell A, Baldessarini RJ (1981) Effects of prenatal treatment of rats with haloperidol due to altered drug distribution in neonatal brain. Neuropharmacology 20:931–939
Mahju MA, Maickel RP (1969) Accumulation of phenothiazine tranquilizers in rat brain and plasma after repeated dosage. Biochem Pharmacol 18:2701–2710
McLean RA, Welch BL (1971) A common error in assessing the significance of percentage change in neuropharmacology. J Pharm Pharmacol 23:643–645
Öhman R, Larsson M, Nilsson IM, Engel J, Carlsson A (1977) neurometabolic and behavioral effects of haloperidol in relation to drug levels in serum and brain. Naunyn-Schmiedeberg's Arch Exp Pathol Pharmakol 299:105–114
Soudijn W, Van Wijngaarden IV, Allewijn F (1967) Distribution, excretion and metabolism of neuroleptics of the butyrophenone type. Part I Excretion: and metabolism of haloperidol and nine related butyrophenone-derivatives in the Wistar rat. Eur J Pharmacol 1:47–57
Tarsy D, Baldessarini RJ (1974) Behavioral supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacology 13:927–940
Teicher MH (1983) MED-65: ALLFIT (APPLESOFT): Adaptation of the ALLFIT Program of DeLean, Munson, and Rodbard for the Apple II microcomputer. Biomedical Computing Technology Center. Vanderbilt University, Nashville, TN
Westerink BHC, Horn AS (1979) Do neuroleptics prevent penetration of dopamine agonists into the brain? Eur J Pharmacol 58:39–48
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Campbell, A., Baldessarini, R.J., Teicher, M.H. et al. Prolonged antidopaminergic actions of single doses of butyrophenones in the rat. Psychopharmacology 87, 161–166 (1985). https://doi.org/10.1007/BF00431801
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00431801